Genmab — Januar 2018
-
Jeg tænkte derfor at BMS ser størst muligheder i tyktarmskræft
-
340 patienter er ganske pænt. I dara-tecentriq NSCLC er der kun 96 patienter
-
OK takker
-
En ny præsentation fra Genmab opsummerer Dara studier ganske fint på de sidste sider: http://files.shareholder.com/downloads/AMDA-KPIBN/5907694987x0x969818/46F507CB-688F-4EBD-9FF6-B7D1C07A7C3E/IR_January_Presentation_29_Jan_18.pdf
-
-
-
Tak doc4. Men stage I er vel ikke " recurrent or metastatic colorectal cancer", som der er tale om i dara-Opdivo-studiet? https://www.clinicaltrials.gov/ct2/show/NCT02060188?term=daratumumab+bms&rank=2
-
Solsen har du link til Bloomberg? Jeg synes ikke jeg kunne finde noget
-
http://www.telegraph.co.uk/science/2018/01/31/cancer-jab-eliminates-tumours-body-even-spread-start-human-trials/ Hvem finder først hvilke to drugs der er tale om ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind